Clinical Trials
232 trialsAn Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase I Comparative Bioavailability Study
AstraZeneca
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NIVALIS
West China Hospital
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
REST
Children's National Research Institute
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
KEYNOTE-603
ModernaTX, Inc.
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
GK01IIT-TZ03
Tianjin Medical University Cancer Institute and Hospital
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
GUARDIAN-02
Tianjin Medical University Cancer Institute and Hospital
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
A Study of DS3610a in Participants With Advanced Solid Tumor
Daiichi Sankyo
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Tcelltech Inc.
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
ATB-320-001A
Autotelicbio
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Incyte Corporation
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CytomX Therapeutics
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
Sound Biopharmaceuticals Ltd.
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors
Takeda
A Study of TAK-103 in Adult With Solid Tumors
Takeda
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Adcentrx Therapeutics
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
BPGbio
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Stemline Therapeutics, Inc.
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
Boehringer Ingelheim